Health Catalyst

HCAT

Börsenwert 130 Mio. $

SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that on September 14, 2026, the Compensation Committee of the Company's Board of Directors granted 2,747,385 restricted stock units (the “RSUs”) to Simeon Kohl under the Health Catalyst, Inc. 2026 Employment Inducement Incentive Plan (the “Inducement Plan”) in connection with Mr. Kohl's previously announced appointment as Chief Executive Officer and President of the Company effective on September 14, 2026. The awards were granted as inducement material to Mr. Kohl's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Reller Joins Health Catalyst as it Enters Its Next Phase of Growth SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", NASDAQ: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Tami Reller has been appointed to its board of directors (Board), effective October 1, 2026.

SALT LAKE CITY, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Simeon Kohl has been appointed Chief Executive Officer (CEO) and President and a member of the Company's Board of Directors, effective September 14, 2026.

SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026.

Health Catalyst NASDAQ: HCAT reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses.

Health Catalyst, Inc. (HCAT) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Health Catalyst (HCAT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.04 per share a year ago.

Company retires all credit facility debt; transaction reflects concentrating its technology on improving health system performance. SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst" or the "Company," Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced it closed the sale of Vitalware, LLC, through which the Company conducted its Vitalware business, to Med-Metrix, LLC, a technology-enabled revenue cycle management company, on July 31, 2026.

SALT LAKE CITY, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended June 30, 2026. “We delivered a very productive second quarter, exceeding the high end of our revenue guidance and the midpoint of our adjusted EBITDA guidance," said Ben Albert, Chief Executive Officer of Health Catalyst.